BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37814344)

  • 1. Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factor.
    Garcia-Manau P; Bonacina E; Serrano B; Caamiña S; Ricart M; Lopez-Quesada E; Vives À; Lopez M; Pintado E; Maroto A; Catalan S; Dalmau M; Del Barco E; Hernandez A; Miserachs M; San Jose M; Armengol-Alsina M; Carreras E; Mendoza M
    Acta Obstet Gynecol Scand; 2023 Dec; 102(12):1711-1718. PubMed ID: 37814344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
    Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
    Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of first-trimester combined screening for early-onset and preterm pre-eclampsia at 8-10 compared with 11-13 weeks' gestation.
    Mendoza M; Garcia-Manau P; Arévalo S; Avilés M; Serrano B; Sánchez-Durán MÁ; Garcia-Ruiz I; Bonacina E; Carreras E
    Ultrasound Obstet Gynecol; 2021 Jan; 57(1):84-90. PubMed ID: 32388877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
    Noël L; Guy GP; Jones S; Forenc K; Buck E; Papageorghiou AT; Thilaganathan B
    Ultrasound Obstet Gynecol; 2021 Oct; 58(4):540-545. PubMed ID: 33998078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis.
    Shen L; Martinez-Portilla RJ; Rolnik DL; Poon LC
    Ultrasound Obstet Gynecol; 2021 Oct; 58(4):546-552. PubMed ID: 33998099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain.
    Cuenca-Gómez D; de Paco Matallana C; Rolle V; Valiño N; Revello R; Adiego B; Mendoza M; Molina FS; Carrillo MP; Delgado JL; Wright A; Santacruz B; Gil MM
    Ultrasound Obstet Gynecol; 2023 Oct; 62(4):522-530. PubMed ID: 37099759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of routine first-trimester combined screening for preeclampsia based on the Gaussian algorithm: A clinical effectiveness study.
    Mendoza M; Bonacina E; Serrano B; Ricart M; Martin L; Lopez-Quesada E; Vives A; Maroto A; Garcia-Manau P; De Antonio C; Tusquets C; Moreano G; Armengol-Alsina M; Carreras E
    Int J Gynaecol Obstet; 2022 Dec; 159(3):803-809. PubMed ID: 35332556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment.
    Wright D; Tan MY; O'Gorman N; Syngelaki A; Nicolaides KH
    BJOG; 2022 Jul; 129(8):1308-1317. PubMed ID: 35015330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population.
    Chaemsaithong P; Pooh RK; Zheng M; Ma R; Chaiyasit N; Tokunaka M; Shaw SW; Seshadri S; Choolani M; Wataganara T; Yeo GSH; Wright A; Leung WC; Sekizawa A; Hu Y; Naruse K; Saito S; Sahota D; Leung TY; Poon LC
    Am J Obstet Gynecol; 2019 Dec; 221(6):650.e1-650.e16. PubMed ID: 31589866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China.
    Hu J; Gao J; Liu J; Meng H; Hao N; Song Y; Ma L; Luo W; Sun J; Gao W; Meng W; Sun Y
    Ultrasound Obstet Gynecol; 2021 Oct; 58(4):529-539. PubMed ID: 33817865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine first-trimester pre-eclampsia screening and risk of preterm birth.
    Giorgione V; Quintero Mendez O; Pinas A; Ansley W; Thilaganathan B
    Ultrasound Obstet Gynecol; 2022 Aug; 60(2):185-191. PubMed ID: 35441764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
    O'Gorman N; Wright D; Syngelaki A; Akolekar R; Wright A; Poon LC; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jan; 214(1):103.e1-103.e12. PubMed ID: 26297382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study.
    Boutin A; Guerby P; Gasse C; Tapp S; Bujold E
    Am J Obstet Gynecol; 2021 Feb; 224(2):204.e1-204.e7. PubMed ID: 32777265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new model for screening for early-onset preeclampsia.
    Serra B; Mendoza M; Scazzocchio E; Meler E; Nolla M; Sabrià E; Rodríguez I; Carreras E
    Am J Obstet Gynecol; 2020 Jun; 222(6):608.e1-608.e18. PubMed ID: 31972161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
    Wright D; Poon LC; Rolnik DL; Syngelaki A; Delgado JL; Vojtassakova D; de Alvarado M; Kapeti E; Rehal A; Pazos A; Carbone IF; Dutemeyer V; Plasencia W; Papantoniou N; Nicolaides KH
    Am J Obstet Gynecol; 2017 Dec; 217(6):685.e1-685.e5. PubMed ID: 28888591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.
    Tan MY; Poon LC; Rolnik DL; Syngelaki A; de Paco Matallana C; Akolekar R; Cicero S; Janga D; Singh M; Molina FS; Persico N; Jani JC; Plasencia W; Greco E; Papaioannou G; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Jul; 52(1):52-59. PubMed ID: 29704277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
    Tan MY; Syngelaki A; Poon LC; Rolnik DL; O'Gorman N; Delgado JL; Akolekar R; Konstantinidou L; Tsavdaridou M; Galeva S; Ajdacka U; Molina FS; Persico N; Jani JC; Plasencia W; Greco E; Papaioannou G; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Aug; 52(2):186-195. PubMed ID: 29896812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASPRE trial: performance of screening for preterm pre-eclampsia.
    Rolnik DL; Wright D; Poon LCY; Syngelaki A; O'Gorman N; de Paco Matallana C; Akolekar R; Cicero S; Janga D; Singh M; Molina FS; Persico N; Jani JC; Plasencia W; Papaioannou G; Tenenbaum-Gavish K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Oct; 50(4):492-495. PubMed ID: 28741785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial.
    Benkő Z; Wright A; Rehal A; Cimpoca B; Syngelaki A; Delgado JL; Tsokaki T; De Alvarado M; Vojtassakova D; Malligiannis Ntalianis K; Chaveeva P; Del Campo A; De Ganzo T; Resta C; Atanasova V; Accurti V; Villalain C; Aguilera J; Dojcinovska D; O'Gorman N; Plasencia W; Zingler E; Dutemeyer V; Alvar B; Casanova MC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Feb; 57(2):257-265. PubMed ID: 33142361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.